CVRx Past Earnings Performance

Past criteria checks 0/6

CVRxDie Erträge des Sektors -25.3% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Medical Equipment growing auf 9.1% pro Jahr stiegen. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 58% pro Jahr gesunken.

Key information

-22.3%

Earnings growth rate

82.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate56.5%
Return on equity-54.2%
Net Margin-104.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Feb 29
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

Nov 11
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

Aug 20
Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

CVRx Pursues Revenue Growth But Operating Losses Worsen

Aug 05

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

Jun 21

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Apr 12
We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Feb 18
Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

CVRx: The Path To 7x Investment Returns

Jan 07

CVRx: High Risk And High Potential Reward

Jul 04

Revenue & Expenses Breakdown
Beta

How CVRx makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:CVRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2339-416512
30 Sep 2335-436212
30 Jun 2331-435912
31 Mar 2326-435511
31 Dec 2222-415010
30 Sep 2219-41469
30 Jun 2216-38418
31 Mar 2214-44348
31 Dec 2113-43288
30 Sep 2111-36216
30 Jun 219-33166
31 Mar 217-19126
31 Dec 206-14106
31 Dec 196-1569

Qualität der Erträge: CVRX ist derzeit unrentabel.

Wachsende Gewinnspanne: CVRX ist derzeit unrentabel.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Ergebnisentwicklung: CVRX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 25.3% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von CVRX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: CVRX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (3.7%) erschwert.


Return on Equity

Hohe Eigenkapitalrendite: CVRX hat eine negative Eigenkapitalrendite (-51.4%), da es derzeit unrentabel ist.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.